CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review - Farhood, Bagher; Najafi, Masoud; Mortezaee, Keywan (Journal of cellular physiology, 2019)
Keywords: Animals; Antigens; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Antitumor activity; Apoptosis; Cancer; cancer cells; Cancer immunotherapy; CD4 antigen; CD8 antigen; CD8+ cytotoxic T lymphocytes (CTLs); Cell activation; Cell Communication - drug effects; CTL‐associated antigen 4 (CTLA‐4); Cytokines - metabolism; Cytotoxicity; Dendritic cells; dendritic cells (DCs); Exhaustion; Fibroblasts; Humans; Immune checkpoint; Immune system; Immunity; Immunological tolerance; Immunoregulation; Immunosuppression; Immunotherapy; Immunotherapy - adverse effects; Inflammation; Innate immunity; interferon‐γ (IFN‐γ); Lymphocyte Activation - drug effects; Lymphocytes; Lymphocytes T; Lymphocytes, Tumor-Infiltrating - drug effects; Lymphocytes, Tumor-Infiltrating - immunology; Lymphocytes, Tumor-Infiltrating - metabolism; Macrophages; Natural killer cells; Neoplasms - immunology; Neoplasms - metabolism; Neoplasms - pathology; Neoplasms - therapy; PD-1 protein; PD-L1 protein; Priming; programmed death‐1 receptor (PD‐1)–ligand (PD‐L1); Receptors; regulatory T cells (Tregs); Signal Transduction; T-Lymphocytes, Cytotoxic - drug effects; T-Lymphocytes, Cytotoxic - immunology; T-Lymphocytes, Cytotoxic - metabolism; Tumor Escape - drug effects; Tumor Microenvironment; tumor microenvironment (TME); Tumors; dendritic cells (DCs); tumor microenvironment (TME); CD8+ cytotoxic T lymphocytes (CTLs); regulatory T cells (Tregs); immunotherapy; cancer cells; CTL-associated antigen 4 (CTLA-4); interferon-γ (IFN-γ); programmed death-1 receptor (PD-1)-ligand (PD-L1)